Insider Makes Significant Stock buy in Melinta Therapeutics (MLNT) Shares Breaks neutral Trend of Last 90 Days

Tuesday, January 09, 2018 10:15 PM ET

Insider Makes Significant Stock buy in Melinta Therapeutics (MLNT) Shares Breaks neutral Trend of Last 90 Days

There was substantial buying activity in Melinta Therapeutics shares by an insider today, as revealed in a form 4 document filed with the SEC. One insider — Vatera Healthcare Partners LLC, 10% Owner and Director — acquired 3,777,778 shares in the company having a market value of approximately $51,000,003. This is the first insider buy/sell trade in the past 90 days.

The level of buy-sell trading at Melinta Therapeutics is near the 280 member peer company average. The Bio Therapeutic Drugs peer group saw 327 buy/sell trades during this period for an average of 1.2 transactions per company. However, the number of shares per buy/sell trade transacted by Melinta Therapeutics insiders is higher. Within the peer group there were 42,573,637 shares purchased and 40,626,427 shares sold with company insiders having bought 9,272 shares on average.

For the purpose of evaluating significant insider buying and selling all trades reported to the SEC that involve awards, options, exercise of derivative securities, company buy-backs, taxes, gifts, shares acquired via inheritance and tenders or exchange offers have been eliminated in data used to create and write this story.

Using proprietary Natural Language Generation (NLG) technology, UpTick evaluates corporate insider filings reported to the SEC and creates real-time news and analysis to report the most significant insider transactions based on transaction type, size and historical trends.

For more information, contact UpTick at info@uptickdata.com. Copyright 2018 UpTick Data Technologies. All rights reserved.

This entry was posted in InsiderNews and tagged , , , , . Bookmark the permalink.